Bayesian Health

The model is the product and the company is explicit about the architectural claim behind it. Real time machine learning models run inside the EHR, learning from messy multimodal structured and unstructured data streams, and the company positions its approach as adaptive rather than one size fits all, taking into account patient population diversity, how clinicians actually deliver care at a given site, and the characteristics of each health system. That per site adaptation is a substantive design position, not a marketing line, and it is what the published research attributes the accuracy and adoption gains to.

The system alerts rather than acts, which is the correct and conservative posture for deterioration detection, and the company treated clinician acceptance as a research question rather than an assumption. One of its three published studies specifically examined clinicians' experiences with the deployed system and concluded that human machine teaming is key to adoption, with over 4,000 caregivers participating in the prospective deployment. Studying whether providers trust and act on the alert, and publishing the result, is a materially higher standard than shipping an alert and reporting an AUC.

Transparency here comes through the peer reviewed literature rather than a datasheet, which is the stronger form. Three studies published in Nature Medicine and npj Digital Medicine describe the approach, the deployment, and the clinician experience, with cohort sizes and settings disclosed, so an external reviewer can examine the methodology directly. The company also publishes the specific claim that its approach produces fewer false alerts than prior systems, which is the metric alert fatigue turns on and one that competitors rarely commit to in print.

The strongest clinical evidence base of any vendor in this index. Three large prospective multi site cohort studies conducted with Johns Hopkins across five academic and community hospitals over a five year period, spanning 764,707 patient encounters of which 17,538 involved sepsis, with 2,000 plus providers using the software during 2.5 years of prospective deployment. Reported outcomes include roughly 20 percent lower likelihood of sepsis death, detection hours earlier than traditional vital sign scoring, and one in three cases caught by the system first. The company's own framing is notable and defensible: this was presented as the first time lives saved were associated with a clinically deployed AI platform. Buyers should still note the studies were conducted in collaboration with the founder's own academic institution.

No published PHI framework or data governance disclosure was located on the company's own materials. The platform reads live EHR data including clinical notes across every hospital department, which is among the broadest data access surfaces in this index, and the absence of published stewardship terms is a gap worth closing directly in diligence.

No HIPAA or BAA statement was located in public materials. Business associate arrangements are structurally required given live EHR integration at named health systems and certainly exist contractually, but nothing is published.

No SOC 2, HITRUST, or ISO 27001 attestation was located, and no trust center was found. For a vendor with this much published clinical rigor, the absence of published security attestation is a conspicuous asymmetry.

No FDA clearance is claimed and none was located. This is the axis buyers should examine most carefully for this vendor, because the product sits closer to the Software as a Medical Device boundary than most clinical decision support: it identifies patients at risk of a specific life threatening condition and prompts clinical action. Under the 21st Century Cures Act, decision support that allows a clinician to independently review the basis for a recommendation can fall outside device regulation, which is the likely position here, but no public statement addresses the regulatory rationale.

Better engagement with this than almost any vendor in the index, though it is embedded in the technical approach rather than presented as a governance program. The company's core stated argument is that one size fits all models fail because they ignore patient population diversity and site specific care delivery patterns, and its adaptive approach is the response to exactly that failure mode. The prospective studies span both academic and community hospital settings, which tests generalization across meaningfully different populations. Falls short of an A because no formal governance framework, monitoring commitment, or subgroup performance breakdown was located.

Integration is the delivery mechanism and it is unusually well substantiated. Models run inside the EHR in real time rather than in a parallel dashboard, and the founding team publicly reported partnering with both of the two largest electronic health record vendors specifically so the tool could be implemented at other hospitals. Reading live clinical notes plus structured data and delivering alerts into clinician workflow across every department, including the emergency department, is the deep end of this axis.

No hosting, tenancy, or data residency terms are published. The stated per health system adaptation of models raises the question of whether model artifacts trained on one institution's data are isolated from others, which a buyer should ask directly.

No published pricing or commercial structure. Enterprise health system contracting is the evident model given the deployment profile, but nothing about cost, per bed or per encounter basis, or implementation commitment is disclosed.

Acute inpatient care is the proven setting, with the published evidence spanning five hospitals across academic and community settings and every department including the emergency department. The company describes the platform as configurable to a wider array of condition specific use cases including clinical deterioration, pressure injuries, palliative care, transitions of care, and recovery at home. Buyers should note the crucial distinction: sepsis is the use case with published prospective evidence, and the others are stated platform capabilities without comparable published validation.